ACB — Aurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: Increased by 7% to $94.2 million, driven by a 12% rise in global medical cannabis revenue.
• Adjusted Gross Margin: Rose 100 basis points to 62%, with medical cannabis margins at 69%.
• Adjusted EBITDA: Reported at $18.5 million, down from $19.4 million year-over-year.
• Adjusted Net Income: $7.2 million, relatively stable compared to $7.4 million in the prior year.
• Free Cash Flow: Positive at $15.5 million, though decreased from $27.4 million in the previous year.
• Cash Position: Ended the quarter with $154 million in cash and no cannabis-related debt.

2. Strategic Updates and Business Highlights

• Market Focus: Aurora is shifting resources away from lower-margin Canadian consumer cannabis to prioritize global medical cannabis, where it sees greater growth potential.
• Market Exits: Plans to exit select Canadian consumer cannabis markets to enhance profitability and streamline operations.
• Divestiture: Selling its controlling stake in Bevo, its plant propagation business, to focus on higher-margin medical cannabis segments.
• International Growth: Strong performance in Germany, Poland, and Australia, with significant market shares and ongoing product introductions.
• New ATM Program: Established an at-the-market equity program to raise up to $100 million for strategic initiatives, including cultivation capacity and potential M&A.

3. Forward Guidance and Outlook

• Annual Global Medical Cannabis Revenue: Expected to range between $269 million and $281 million, reflecting 10% to 15% growth.
• Consolidated Adjusted EBITDA: Anticipated to increase to between $52 million and $57 million for the fiscal year, representing 5% to 10% annual growth.
• Continued Focus: Emphasis on maintaining strong margins and operational efficiencies in the medical cannabis segment.

4. Challenges and Points of Concern

• Consumer Cannabis Decline: Revenue from the consumer cannabis segment fell 48% to $5.2 million, a strategic decision reflecting the shift in focus.
• Market Pressures: Increased competition in Germany leading to price pressures, particularly in the value segment.
• Operational Costs: Higher SG&A expenses due to increased professional fees and headcount in expanding markets.
• Regulatory Risks: Ongoing changes in regulatory frameworks, particularly in Germany and Poland, may pose challenges to maintaining market share and profitability.

5. Notable Q&A Insights

• Market Exit Strategy: Management indicated that exiting lower-margin consumer cannabis markets will enhance overall financial results and allow for better allocation of resources.
• Australian Market Transition: The shift towards premium products in Australia is expected to take time but is seen as non-disruptive and beneficial to margins.
• Supply Chain and Production: Aurora produces nearly all of its products internally, which is crucial for maintaining quality and meeting GMP standards.
• U.S. Market Potential: Management remains optimistic about potential U.S. market entry following regulatory changes but emphasizes that rescheduling alone does not equate to federal legalization.

Overall, Aurora Cannabis is strategically repositioning itself to capitalize on the growing global medical cannabis market while navigating challenges in the consumer segment and regulatory landscape.